Virtual Radiologic Corp. (VRC; Minnetonka, Minnesota) reported that it hopes to raise up to $82.8 million from its previously disclosed IPO scheduled to debut this week, according to documents filed with the U.S. Securities and Exchange Commission.

The company, which provides radiology services to hospitals, clinics and imaging centers, estimates that the IPO will fetch between $16 and $18 a share for the company’s 4.6 million shares. The stock is expected to begin trading Thursday on the Nasdaq Stock Market under the symbol VRAD.

The company, which first reported filing for its IPO in August, said that it intends to use the proceeds from the offering for the repayment of the outstanding debt under the term loan under its senior credit facility (about $41 million of the proceeds); the further development and expansion of its service offerings (about $5 million of the proceeds); the recruitment of additional radiologists and increased sales and marketing initiatives (about $2 million of the proceeds); and working capital and general corporate purposes (about $13.7 million of proceeds).

Goldman, Sachs & Co., Merrill Lynch & Co. and William Blair & Co. are the underwriters, and will have an option to purchase an additional 600,000 shares to cover any over-allotments.

Founded in 2004, VRC employs radiologists across the country who can interpret and analyze imaging data from CT scans, MRIs and ultrasounds 24 hours a day using encrypted broadband networks.

Last year, the company reported $54.1 million in revenue, compared with $12.9 million in 2004. For the nine months ended Sept. 30, the company earned a profit of $2.2 million.

VRC was formed through a merger between Virtual Radiologic Consultants, a Minnesota corporation, and Virtual Radiologic Consultants, a Delaware corporation, that was consummated on May 2, 2005. On Jan. 1, 2006, Virtual Radiologic Consultants, the Delaware corporation and the surviving entity in the merger, changed its name to Virtual Radiologic Corporation.

Inverness Medical Innovations (IMI; Waltham, Massachusetts) reported that it is offering to sell 7 million shares of its common stock in accordance with a shelf registration statement in an underwritten public offering.

Certain selling stockholders of the company are also offering to sell up to 165,698 shares of common stock in the offering. And the company said it expects to grant the underwriters a 30-day option to purchase up to another 1,074,854 shares of common stock to cover any over-allotments.

IMI said it intends to use the proceeds from the offering for working capital and other general corporate purposes, including the financing of potential acquisitions or other investments, and for capital expenditures.

It said it may also may use a portion of the proceeds to fund its pending $37 million acquisition of Panbio (Brisbane, Australia), a developer of diagnostic tests including those used in the diagnosis of flaviviruses and other arthropod-borne viruses.

In other financing news: Aspect Medical Systems (Norwood. Massachusetts), a developer of brain-monitoring technology, reported that it has entered into a letter agreement with Boston Scientific (Natick, Massachusetts) to waive specified provisions of the termination and repurchase agreement entered into by the companies in June.

Boston Scientific agreed, among other things, that for a period of 180 days after the date of the agreement, it would not sell any of its shares of Aspect common stock to a third party, and it granted to Aspect a call option, exercisable by Aspect in one or more transactions during the 180-day period, to purchase up to all of its remaining shares held of record by Boston Sci on the date of the agreement.

Aspect has agreed to waive the lock-up and the call option set forth in the agreement with respect to the remaining 1,513,239 shares of Aspect currently held of record by Boston Sci because that company and a third party, OrbiMed Advisors, have reached an agreement for OrbiMed to purchase all of those shares. The parties have also agreed to terminate the registration rights agreement dated June 11, by the companies relating to those shares.

In June, the companies agreed to end a collaboration to develop brain-monitoring products aimed at assisting clinicians in the diagnosis and treatment of depression, Alzheimer’s disease and other neurological conditions.

At the time of the deal termination, Boston Sci held about 6 million Aspect shares, or 27% of shares outstanding.

For the next six months after the deal was scrapped, Aspect had the right to buy back the rest of the shares held by Boston Sci for $15 a share, or the average closing price of Aspect stock over the 10 trading days prior to Aspect exercising its right to repurchase, whichever is higher. Boston Scientific had also agreed not to sell any of its Aspect stock, except to Aspect, during the six-month period.

The neuroscience alliance was established in May 2005 and involved a commitment by BostonSc of $25 million over five years to support research by Aspect in the depression and Alzheimer’s markets. Boston Sci had provided roughly $10 million of the $25 million originally committed.